Angiolillo Dominick J, Guzman Luis A, Bass Theodore A
Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL 32209, USA.
Am Heart J. 2008 Aug;156(2 Suppl):S3-9. doi: 10.1016/j.ahj.2008.06.003.
Antiplatelet therapy is the current criterion standard for the treatment of patients undergoing percutaneous coronary intervention and patients who have acute coronary syndromes. Clopidogrel in combination with aspirin is the current standard of care for reducing cardiovascular events in these patients. However, patients who receive currently available antiplatelet therapy may still develop atherothrombotic events. In addition, despite the clinical benefits achieved with clopidogrel, significant clinical limitations are associated with its use. This article summarizes the current understanding of the benefits and limitations of the commonly used antiplatelet therapies.
抗血小板治疗是目前接受经皮冠状动脉介入治疗的患者以及患有急性冠状动脉综合征的患者的标准治疗方法。氯吡格雷联合阿司匹林是目前用于降低这些患者心血管事件的标准治疗方案。然而，接受当前可用抗血小板治疗的患者仍可能发生动脉粥样硬化血栓形成事件。此外，尽管氯吡格雷取得了临床益处，但其使用仍存在显著的临床局限性。本文总结了目前对常用抗血小板治疗的益处和局限性的认识。
